비소세포폐암(NSCLC) 시장 : 유형별, 치료별, 최종사용자별, 지역별

Global Non-Small Cell Lung Cancer Market is estimated to be valued at USD 28.61 Bn in 2025 and is expected to reach USD 54.38 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.6% from 2025 to 2032.

Figure. Non-Small Cell Lung Cancer Market Share (%), By Region 2025

Non-small cell lung cancer (NSCLC) is the most prevalent type of lung cancer that accounts for around 85% of all lung cancers. It is among the leading causes of cancer-related deaths worldwide. Global non-small cell lung cancer market growth is driven by factors like rising prevalence of smoking habits and environmental pollution, increasing research & development activities for advanced treatment options and growing demand for targeted and personalized medicines. However, high treatment costs hampers the market growth.

Market Dynamics:

Global non-small cell lung cancer market growth is driven by increasing prevalence of smoking across both developed and developing nations, growing environmental pollution levels and aging population. According to WHO, around 1.80 million new lung cancer cases are reported globally each year, majority of which are NSCLC. Advancements in targeted therapies and cancer treatment modalities offers opportunities for market players. However, high costs associated with targeted drugs and lack of awareness in low-income countries hampers the market growth. Moreover, risk of drug failure during trials also negatively impacts R&D activities.

Key features of the study:

• This report provides in-depth analysis of the global non-small cell lung cancer market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global non-small cell lung cancer market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include AstraZeneca, Pfizer Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Celgene Corporation, Merck KGaA, Johnson & Johnson.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global non-small cell lung cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global non-small cell lung cancer market.

Detailed Segmentation-

• By Type
  • Adenocarcinoma
  • Squamous Cell Carcinoma
  • Large Cell Carcinoma
  • Large Cell Neuroendocrine Tumors
• Treatment
  • Chemotherapy
  • Targeted Therapy
  • Bevacizumab
  • Necitumumab
  • Ramucirumab
  • Immunotherapy
  • Nivolumab
  • Atezolizumab
  • Others
• End User
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Hoffmann-La Roche Ltd
  • Honeywell International Inc.
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Eli Lilly and Company
  • Boehringer Ingelheim International GmbH
  • Celgene Corporation
  • Amgen Inc.
  • Johnson & Johnson
  • Gilead Sciences, Inc.
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Sanofi
  • Teva Pharmaceutical

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Type
  • Market Snapshot, By Treatment
  • Market Snapshot, By End User
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Non-Small Cell Lung Cancer Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Non-Small Cell Lung Cancer Market, By Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Adenocarcinoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Squamous Cell Carcinoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Large Cell Carcinoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Large Cell Neuroendocrine Tumors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Non-Small Cell Lung Cancer Market, By Treatment, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Chemotherapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Targeted Therapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Bevacizumab (Avastin)
• Necitumumab (Portrazza)
• Ramucirumab (Cyramza)
• Immunotherapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Nivolumab (Opdivo)
• Atezolizumab (Tecentriq)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Non-Small Cell Lung Cancer Market, By End User, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Hospitals
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Home Care
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Specialty Clinics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Non-Small Cell Lung Cancer Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • F. Hoffmann-La Roche Ltd
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Honeywell International Inc.
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • AstraZeneca PLC
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Eli Lilly and Company
  • Boehringer Ingelheim International GmbH
  • Celgene Corporation
  • Amgen Inc.
  • Johnson & Johnson
  • Gilead Sciences, Inc.
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. Section

• References
• Research Methodology
• About Us and Sales Contact

"